The combined drug networks, particularly those involving Cetuximab, Erlotinib, and Lapatinib, demonstrate how targeting multiple genes and pathways can potentially overcome resistance mechanisms commonly encountered in HER2+ breast cancer treatment. The gene discussed is ERBB2; the disease is breast carcinoma.